Development Center for Biotechnology (DCB)

GenomeFrontier has partnered with the Development Center for Biotechnology on a collaborative research project to perform animal studies on the safety, efficacy, pharmacokinetics and pharmacodynamics of GF-CART02, a multiplex armored dual targeting autologous CAR T cell therapy for multiple myeloma.